Critical appraisal of neuropathic pain guidelines in Asia
Neuropathic pain (NP) is type of chronic pain that is common and often difficult to treat. Clinicians may be guided by a number of published guidelines and algorithms for the management of neuropathic pain. It is important for every clinician to know the quality of guidelines. The availability of cu...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Universitas Gadjah Mada
2019-04-01
|
Series: | Journal of the Medical Sciences |
Subjects: | |
Online Access: | https://jurnal.ugm.ac.id/bik/article/view/26601 |
id |
doaj-b511f5d0a5ea4a5f9da10e204fd60efe |
---|---|
record_format |
Article |
spelling |
doaj-b511f5d0a5ea4a5f9da10e204fd60efe2020-11-25T01:29:10ZengUniversitas Gadjah MadaJournal of the Medical Sciences0126-13122356-39312019-04-0151123792Critical appraisal of neuropathic pain guidelines in AsiaRizaldy Taslim Pinzon0Rosa De Lima Renita Sanyasi1Faculty of Medicine, Duta Wacana Christian University, Yogyakarta,Panti Rapih Hospital, Yogyakarta, IndonesiaNeuropathic pain (NP) is type of chronic pain that is common and often difficult to treat. Clinicians may be guided by a number of published guidelines and algorithms for the management of neuropathic pain. It is important for every clinician to know the quality of guidelines. The availability of current guideline in Asian countries is not well understood. Critical appraisal of NP guidelines in Asia has not performed, yet. The aim of this study was to appraise the quality of pharmacological treatment from neuropathic pain guidelines in Asia. Systematic searches were conducted by using combination of keywords i.e NP, Asia, and guideline. Guidelines evaluation was using appraisal of guidelines for research & evaluation II (AGREE II) instrument. The result interpreted as (i) a strongly recommended for use in practice if most domains scored above 50%; (ii) recommended for use with some modification if most domains scored between 30% to 50%; or (iii) not recommended for use in practice if most domains scored below 30%. After matched to inclusion and exclusion criteria there were 5 guidelines left: a guideline from Philippines, China, South Korea, Malaysia and Middle East. All of guidelines are recommended for use with some modification. The guidelines mention that first line treatment for NP are tricyclic antidepressants, selective norepinephrine reuptake inhibitor (SNRI) and alpha 2-delta ligand calcium channel blocker (CCB). Most of the evidences come from peripheral NP. There were limited evidences for the treatment of central neuropathic pain (central post stroke pain and pain after spinal cord injury). All the existing guideline mention, that the first line treatment for neuropathic are the tricyclic antidepressants, SNRI and alpha 2-delta ligand CCB.https://jurnal.ugm.ac.id/bik/article/view/26601systematic review, neuropathic pain, guidelines, asia |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Rizaldy Taslim Pinzon Rosa De Lima Renita Sanyasi |
spellingShingle |
Rizaldy Taslim Pinzon Rosa De Lima Renita Sanyasi Critical appraisal of neuropathic pain guidelines in Asia Journal of the Medical Sciences systematic review, neuropathic pain, guidelines, asia |
author_facet |
Rizaldy Taslim Pinzon Rosa De Lima Renita Sanyasi |
author_sort |
Rizaldy Taslim Pinzon |
title |
Critical appraisal of neuropathic pain guidelines in Asia |
title_short |
Critical appraisal of neuropathic pain guidelines in Asia |
title_full |
Critical appraisal of neuropathic pain guidelines in Asia |
title_fullStr |
Critical appraisal of neuropathic pain guidelines in Asia |
title_full_unstemmed |
Critical appraisal of neuropathic pain guidelines in Asia |
title_sort |
critical appraisal of neuropathic pain guidelines in asia |
publisher |
Universitas Gadjah Mada |
series |
Journal of the Medical Sciences |
issn |
0126-1312 2356-3931 |
publishDate |
2019-04-01 |
description |
Neuropathic pain (NP) is type of chronic pain that is common and often difficult to treat. Clinicians may be guided by a number of published guidelines and algorithms for the management of neuropathic pain. It is important for every clinician to know the quality of guidelines. The availability of current guideline in Asian countries is not well understood. Critical appraisal of NP guidelines in Asia has not performed, yet. The aim of this study was to appraise the quality of pharmacological treatment from neuropathic pain guidelines in Asia. Systematic searches were conducted by using combination of keywords i.e NP, Asia, and guideline. Guidelines evaluation was using appraisal of guidelines for research & evaluation II (AGREE II) instrument. The result interpreted as (i) a strongly recommended for use in practice if most domains scored above 50%; (ii) recommended for use with some modification if most domains scored between 30% to 50%; or (iii) not recommended for use in practice if most domains scored below 30%. After matched to inclusion and exclusion criteria there were 5 guidelines left: a guideline from Philippines, China, South Korea, Malaysia and Middle East. All of guidelines are recommended for use with some modification. The guidelines mention that first line treatment for NP are tricyclic antidepressants, selective norepinephrine reuptake inhibitor (SNRI) and alpha 2-delta ligand calcium channel blocker (CCB). Most of the evidences come from peripheral NP. There were limited evidences for the treatment of central neuropathic pain (central post stroke pain and pain after spinal cord injury). All the existing guideline mention, that the first line treatment for neuropathic are the tricyclic antidepressants, SNRI and alpha 2-delta ligand CCB. |
topic |
systematic review, neuropathic pain, guidelines, asia |
url |
https://jurnal.ugm.ac.id/bik/article/view/26601 |
work_keys_str_mv |
AT rizaldytaslimpinzon criticalappraisalofneuropathicpainguidelinesinasia AT rosadelimarenitasanyasi criticalappraisalofneuropathicpainguidelinesinasia |
_version_ |
1725098121897181184 |